ASCO 2026: Skipping axillary lymph node dissection safe for some breast cancer patients
A Phase III clinical trial presented at the 2026 ASCO meeting indicates that omitting axillary lymph node dissection is safe for certain breast cancer patients. This approach helps patients avoid long-term arm-related side effects without compromising safety.
Why it matters
This finding could significantly improve the quality of life for thousands of breast cancer patients by reducing unnecessary surgical complications.
ASCO 2026: Skipping axillary lymph node dissection safe for some breast cancer patients - Oncology Central
The article reports on medical research findings in a neutral, objective manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in